Literature DB >> 25447947

Cystic fibrosis--what are the prospects for a cure?

Shankar Kumar, Anand Tana, Anu Shankar.   

Abstract

Significant improvements in the treatment of cystic fibrosis over the last few decades have altered this lethal disease in children to a multisystem disorder with survival into adult life now common. In most developed countries the numbers of adult cystic fibrosis patients outnumber children. This is mainly due to improvements in care during early life. The principal cause of morbidity and mortality is pulmonary disease, and so the focus of new treatments has targeted the lungs. Identification of the underlying gene defect in the cystic fibrosis transmembrane conductance regulator has ushered in a new era in cystic fibrosis research, with prospects of a cure. In this article, we review the most exciting recent advances that correct defects in cellular processing, chloride channel function and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25447947     DOI: 10.1016/j.ejim.2014.09.018

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

1.  Shining new light on newborn screening of cystic fibrosis in the province of Quebec.

Authors:  Léticia Khendek
Journal:  Can J Public Health       Date:  2017-09-14

Review 2.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

Review 3.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

4.  The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.

Authors:  Romina Fiorotto; Ambra Villani; Antonis Kourtidis; Roberto Scirpo; Mariangela Amenduni; Peter J Geibel; Massimiliano Cadamuro; Carlo Spirli; Panos Z Anastasiadis; Mario Strazzabosco
Journal:  Hepatology       Date:  2016-10-27       Impact factor: 17.425

Review 5.  In Vivo Assessment of Mitochondrial Dysfunction in Clinical Populations Using Near-Infrared Spectroscopy.

Authors:  T Bradley Willingham; Kevin K McCully
Journal:  Front Physiol       Date:  2017-09-14       Impact factor: 4.566

6.  Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies.

Authors:  Justin S Antony; Alexander Dewerth; Ashiqul Haque; Rupert Handgretinger; Michael S D Kormann
Journal:  Mol Cell Pediatr       Date:  2015-11-20

Review 7.  Mutations of the cystic fibrosis transmembrane conductance regulator gene in males with congenital bilateral absence of the vas deferens: Reproductive implications and genetic counseling (Review).

Authors:  Xiangrong Cui; Xueqing Wu; Qiang Li; Xuan Jing
Journal:  Mol Med Rep       Date:  2020-08-24       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.